Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo ...

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.

Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

While many of the top income stocks on the market are expensive, some can be had for well under $100 per share. Here are two ...

Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and ...